Trading is risicovol
Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect.
Trading is risicovol
Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect.
GE HealthCare Technologies
Gesloten
SectorGezondheidszorg
75.11 -1.75
Overzicht
Wijziging aandelenprijs
24u
Min
74.94
Max
75.67
Inkomsten | -150M 588M |
|---|---|
Verkoop | -542M 4.8B |
K/W Sectorgemiddelde | 15.674 39.564 |
EPS | 1.01 |
Dividendrendement | 0.19 |
Winstmarge | 12.309 |
Werknemers | 53,000 |
EBITDA | -456M 629M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +10.55% upside |
Dividendrendement Sectorgemiddelde | 0.19% 2.40% |
|---|---|
Volgende Winsten | 30 jul 2025 |
Volgende dividenddatum | 15 aug 2025 |
Volgende Ex Dividend datum | 25 jul 2025 |
Marktkapitalisatie | -7.7B 34B |
|---|---|
Vorige openingsprijs | 76.86 |
Vorige sluitingsprijs | 75.11 |
Nieuwssentiment
By Acuity
22%
78%
50 / 376 Rangschikking in Healthcare
GE HealthCare Technologies Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
GE HealthCare Technologies Prognose
Koersdoel
By TipRanks
10.55% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 84.57Ā USDĀ 10.55%
Hoogste 95Ā USD
Laagste 73Ā USD
Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor GE HealthCare Technologies - Dist. in de afgelopen 3 maanden.
Sentiment
By Acuity
50 / 376 Rangschikking in Gezondheidszorg
Nieuwssentiment
Zeer Sterk Bearish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over GE HealthCare Technologies
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
